DK1648940T3 - Reduktion af udvaskning af protein A under protein A-affinitetskromatografi - Google Patents
Reduktion af udvaskning af protein A under protein A-affinitetskromatografi Download PDFInfo
- Publication number
- DK1648940T3 DK1648940T3 DK04777121.7T DK04777121T DK1648940T3 DK 1648940 T3 DK1648940 T3 DK 1648940T3 DK 04777121 T DK04777121 T DK 04777121T DK 1648940 T3 DK1648940 T3 DK 1648940T3
- Authority
- DK
- Denmark
- Prior art keywords
- protein
- antibody
- antibodies
- humanized
- leaching
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (10)
1. Fremgangsmåde til oprensning af et protein, som omfatter en Chi2/CH3-region, ved hjælp af protein A-affinitetskromatografi, hvor en indledende protein A-kromatografi, der udføres ved en rumtemperatur på mere end 20 °C, resulterer i mere end 20 ng udvasket protein A per mg protein, som er til stede i en oprenset sammensætning, hvilken fremgangsmåde omfatter: (a) at udsætte en prøve af proteinet og en eller flere urenheder for protein A-affinitetskromatografi, hvor prøvens temperatur ved en reduceret temperatur er i området fra 3 °C til 15 °C, (b) at genindvinde den oprensede sammensætning, der er opnået, og (c) at måle det udvaskede protein A i den oprensede sammensætning, hvor udvaskningen af protein A er reduceret i den oprensede sammensætning, der er opnået ved den reducerede temperatur, og den oprensede sammensætning indeholder 0 ng protein A til 15 ng protein A per mg protein.
2. Fremgangsmåde ifølge krav 1, yderligere omfattende at udsætte sammensætningen, som har været underkastet protein A-affinitetskromatografi, for en proteaseinhibitor.
3. Fremgangsmåde ifølge krav 2, hvorved proteaseinhibitoren er EDTA eller 4-(2-aminoethyl)-benzensulfonyl-fluorid, hydrochlorid (AEBSF).
4. Fremgangsmåde ifølge krav 1, hvorved proteinet er et antistof.
5. Fremgangsmåde ifølge krav 4, hvorved antistoffet binder et antigen, udvalgt fra gruppen bestående af FIER2, vaskulær endothelial vækstfaktor (VEGF), IgE, CD20, CD40, CD11a, vævsfaktor (TF), prostatastamcelleanti-gen (PSCA), interleukin-8 (IL-8), epidermal vækstfaktorreceptor (EGFR), HER3, HER4, α4β7 og α5β3.
6. Fremgangsmåde ifølge krav 4, hvorved antistoffet udvælges fra gruppen bestående af trastuzumab, humaniseret 2C4, humaniseret CD11a-antistof og humaniseret VEGF-antistof.
7. Fremgangsmåde ifølge krav 4, hvorved antistoffet binder HER2-antigen.
8. Fremgangsmåde ifølge krav 7, hvorved antistoffet er trastuzumab eller humaniseret 2C4.
9. Fremgangsmåde ifølge krav 1, hvorved proteinet er et immunoadhesin.
10. Fremgangsmåde ifølge krav 9, hvorved inmunoadhesinet er et TNF-receptor- immunoadhesin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49050003P | 2003-07-28 | 2003-07-28 | |
PCT/US2004/020480 WO2005016968A2 (en) | 2003-07-28 | 2004-06-24 | Reducing protein a leaching during protein a affinity chromatography |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1648940T3 true DK1648940T3 (da) | 2016-08-15 |
Family
ID=34193088
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16164203.8T DK3095793T3 (da) | 2003-07-28 | 2004-06-24 | Reducering af udvaskning af protein A under en protein A-affinitetskromatografi |
DK04777121.7T DK1648940T3 (da) | 2003-07-28 | 2004-06-24 | Reduktion af udvaskning af protein A under protein A-affinitetskromatografi |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16164203.8T DK3095793T3 (da) | 2003-07-28 | 2004-06-24 | Reducering af udvaskning af protein A under en protein A-affinitetskromatografi |
Country Status (14)
Country | Link |
---|---|
US (2) | US7485704B2 (da) |
EP (3) | EP3722309A1 (da) |
JP (1) | JP4599355B2 (da) |
AU (1) | AU2004265253B2 (da) |
CA (1) | CA2531595C (da) |
DK (2) | DK3095793T3 (da) |
ES (1) | ES2786568T3 (da) |
HR (1) | HRP20200589T1 (da) |
HU (2) | HUE050171T2 (da) |
LT (1) | LT3095793T (da) |
PL (2) | PL1648940T3 (da) |
PT (1) | PT3095793T (da) |
SI (2) | SI1648940T1 (da) |
WO (1) | WO2005016968A2 (da) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
DK3095793T3 (da) | 2003-07-28 | 2020-05-25 | Genentech Inc | Reducering af udvaskning af protein A under en protein A-affinitetskromatografi |
WO2005037869A2 (en) * | 2003-10-15 | 2005-04-28 | Applera Corporation | Method of reducing leachate from protein a affinity media |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US7483344B2 (en) | 2005-02-14 | 2009-01-27 | Quantum Corporation | Compact picker systems and methods for automated storage libraries |
ES2440481T3 (es) * | 2005-02-23 | 2014-01-29 | Genentech, Inc. | Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab |
WO2006110292A2 (en) * | 2005-03-25 | 2006-10-19 | The Regents Of The University Of California | Temperature-triggered immobilization and purification of antibodies |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US8940871B2 (en) | 2006-03-20 | 2015-01-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
BRPI0716762A2 (pt) | 2006-09-13 | 2013-09-24 | Abbott Lab | melhorias da cultura celular |
NZ577933A (en) * | 2007-01-22 | 2011-12-22 | Genentech Inc | Polyelectrolyte precipitation and purification of antibodies |
WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
KR20190140090A (ko) | 2007-07-09 | 2019-12-18 | 제넨테크, 인크. | 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지 |
JP6126773B2 (ja) * | 2007-09-04 | 2017-05-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原(psca)抗体 |
EP2740490A1 (en) * | 2007-10-03 | 2014-06-11 | Cornell University | Treatment of proliferative disorders using antibodies to PSMA |
TWI472339B (zh) * | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
US9029508B2 (en) * | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
CN102027010A (zh) * | 2008-05-15 | 2011-04-20 | 诺沃-诺迪斯克有限公司 | 抗体纯化方法 |
PE20100092A1 (es) * | 2008-06-03 | 2010-03-12 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
PE20100054A1 (es) * | 2008-06-03 | 2010-03-03 | Abbott Lab | Inmunoglobulina con dominio variable dual |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
RU2011104348A (ru) * | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение |
US20100069616A1 (en) * | 2008-08-06 | 2010-03-18 | The Regents Of The University Of California | Engineered antibody-nanoparticle conjugates |
MX2011001696A (es) * | 2008-08-14 | 2011-03-25 | Merck Sharp & Dohme | Metodos para purificar anticuerpos usando cromatografia de afinidad con proteina a. |
EP2335076B1 (en) * | 2008-09-15 | 2012-08-08 | EMD Millipore Corporation | Methods for quantifying protein leakage from protein based affinity chromatography resins |
CA2738499A1 (en) | 2008-10-20 | 2010-04-29 | Abbott Laboratories | Viral inactivation during purification of antibodies |
EP2921501A1 (en) | 2008-10-20 | 2015-09-23 | Abbvie Inc. | Isolation and purification of antibodies using Protein A affinity chromatography |
SG195555A1 (en) † | 2008-12-24 | 2013-12-30 | Emd Millipore Corp | Caustic stable chromatography ligands |
ES2712732T3 (es) * | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico |
CN102395597A (zh) | 2009-03-11 | 2012-03-28 | 惠氏有限责任公司 | 纯化小模块免疫药物蛋白的方法 |
MX346002B (es) | 2009-06-17 | 2017-03-01 | Abbvie Biotherapeutics Inc | Anticuerpos anti-vegf y sus usos. |
TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
WO2011015920A2 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A highly efficient process of purification and production of recombinant trastuzumab |
NZ598929A (en) * | 2009-09-01 | 2014-05-30 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
AR078651A1 (es) * | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
EP2506876B1 (en) | 2009-12-02 | 2016-10-12 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
US20130178608A1 (en) * | 2009-12-29 | 2013-07-11 | Samir Kulkarni | Protein purification by ion exchange |
US20130116413A1 (en) * | 2009-12-29 | 2013-05-09 | Dr. Reddy's Laboratories, Inc. | Purification of proteins |
WO2011153243A2 (en) * | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Anti-angiogenesis therapy for treating gastric cancer |
MY160445A (en) | 2010-08-03 | 2017-03-15 | Abbvie Inc | Dual Variable Domain Immunoglobulins And Uses Thereof |
JP2013539364A (ja) | 2010-08-26 | 2013-10-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
US9051375B2 (en) | 2010-12-21 | 2015-06-09 | The University Of Western Ontario | Alkali-resistant variants of protein A and their use in affinity chromatography |
US9040661B2 (en) | 2010-12-21 | 2015-05-26 | Jsr Corporation | Support for affinity chromatography and method for isolating immunoglobulin |
CN104334189A (zh) | 2011-10-14 | 2015-02-04 | 霍夫曼-拉罗奇有限公司 | Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品 |
BR112014012539B1 (pt) | 2011-11-23 | 2022-12-20 | Medimmune, Llc | Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo |
EP2797955A2 (en) | 2011-12-30 | 2014-11-05 | AbbVie Inc. | Dual variable domain immunoglobulins against il-13 and/or il-17 |
JP6253584B2 (ja) * | 2012-08-27 | 2017-12-27 | 旭化成メディカル株式会社 | 温度応答性クロマトグラフィーによる抗体の精製方法 |
KR20210111353A (ko) | 2012-11-01 | 2021-09-10 | 애브비 인코포레이티드 | 항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도 |
US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
EP2970459A2 (en) | 2013-03-15 | 2016-01-20 | AbbVie Inc. | Dual specific binding proteins directed against il-1beta and il-17 |
NZ751877A (en) | 2013-04-16 | 2020-04-24 | Genentech Inc | Pertuzumab variants and evaluation thereof |
WO2014186350A1 (en) * | 2013-05-15 | 2014-11-20 | Medimmune Limited | Purification of recombinantly produced polypeptides |
WO2015009701A1 (en) | 2013-07-15 | 2015-01-22 | North Carolina State University | Protease-resistant peptide ligands |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
ES2737078T3 (es) * | 2013-09-04 | 2020-01-10 | Emd Millipore Corp | Cromatografía de Proteína A |
JP6602765B2 (ja) | 2013-09-05 | 2019-11-06 | ジェネンテック, インコーポレイテッド | クロマトグラフィー再使用のための方法 |
WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
KR101921552B1 (ko) * | 2014-03-10 | 2018-11-23 | 리히터 게데온 닐트. | 사전 세정 단계를 이용하는 면역글로불린 정제 |
WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
WO2015164665A1 (en) | 2014-04-25 | 2015-10-29 | Genentech, Inc. | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
EP3169801A1 (en) | 2014-07-14 | 2017-05-24 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for treatment of glioblastoma |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
AR104368A1 (es) | 2015-04-03 | 2017-07-19 | Lilly Co Eli | Anticuerpos biespecíficos anti-cd20- / anti-baff |
CN107614015A (zh) | 2015-05-30 | 2018-01-19 | 豪夫迈·罗氏有限公司 | 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法 |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
EP4137158A1 (en) | 2015-08-07 | 2023-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
JP6851109B2 (ja) * | 2016-06-16 | 2021-03-31 | Jsr株式会社 | 抗体を精製する方法及び担体を洗浄する方法 |
AU2017355432A1 (en) | 2016-11-04 | 2019-05-16 | F. Hoffmann-La Roche Ag | Treatment of HER2-positive breast cancer |
TW201827077A (zh) | 2016-12-28 | 2018-08-01 | 美商建南德克公司 | 晚期her2表現癌症之治療 |
SI3570884T1 (sl) | 2017-01-17 | 2021-02-26 | Genentech, Inc. | Subkutane formulacije protiteles HER2 |
WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
EP3615695A1 (en) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
CA3135846A1 (en) | 2019-04-02 | 2020-10-08 | Bondwell Technologies Inc. | Functionalized ubx protein materials for enhanced purification of antibodies |
EP4038349A4 (en) * | 2019-10-01 | 2022-12-28 | Repligen Corporation | DETERMINATION OF THE PROTEIN CONCENTRATION OF A FLUID |
US11224858B1 (en) | 2020-10-01 | 2022-01-18 | Immunicom, Inc. | Reduced leaching of a ligand |
AU2020470781A1 (en) | 2020-10-01 | 2023-05-18 | Immunicom, Inc. | Reduced leaching of a ligand |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US4983722A (en) | 1988-06-08 | 1991-01-08 | Miles Inc. | Removal of protein A from antibody preparations |
WO1989012463A1 (en) | 1988-06-21 | 1989-12-28 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
EP0602126B1 (en) | 1991-08-14 | 2003-03-05 | Genentech, Inc. | Immunoglobulin variants for specific fc epsilon receptors |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
CA2129663C (en) | 1992-02-06 | 2005-07-05 | James S. Huston | Biosynthetic binding protein for cancer marker |
WO1994004188A1 (en) | 1992-08-21 | 1994-03-03 | Genentech, Inc. | Method for treating an lfa-1-mediated disorder |
WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5714338A (en) | 1993-12-10 | 1998-02-03 | Genentech, Inc. | Methods for diagnosis of allergy |
MX9602818A (es) | 1994-01-18 | 1997-06-28 | Genentech Inc | Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige. |
US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
US5707622A (en) | 1994-03-03 | 1998-01-13 | Genentech, Inc. | Methods for treating ulcerative colitis |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
DE69505991T2 (de) | 1994-07-13 | 1999-04-08 | Sca Hygiene Paper Ab | Verfahren zur herstellung eines vliesstoffes |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
ES2183131T3 (es) | 1996-01-23 | 2003-03-16 | Genentech Inc | Anticuerpos anti-cd18 utilizados contra el ictus cerebral. |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
NO304183B1 (no) * | 1996-11-22 | 1998-11-09 | Nyfotek As | FremgangsmÕte for fremstilling av heksagonal faujasitt med lavt forbruk av organisk tilsetningsstoff, samt anvendelse av denne som katalysator ved alkylering |
DE69739673D1 (de) | 1996-11-27 | 2009-12-31 | Genentech Inc | Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix |
CA2272842C (en) | 1996-11-27 | 2012-05-15 | Genentech, Inc. | Humanized anti-cd11a antibodies |
ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
JP2001511653A (ja) | 1997-05-15 | 2001-08-14 | ジェネンテク,インコーポレイテッド | Apo−2レセプター |
ES2527915T3 (es) | 1998-06-09 | 2015-02-02 | Csl Behring Ag | Producto de inmunoglobulina G (IgG) líquido |
US6927044B2 (en) * | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
SI1189641T1 (sl) | 1999-06-25 | 2009-12-31 | Genentech Inc | Humanizirana protitelesa proti ErbB2 in zdravljenje s protitelesi proti ErbB2 |
DE60039448D1 (de) | 1999-10-29 | 2008-08-21 | Genentech Inc | Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung |
DE10155984A1 (de) | 2001-11-15 | 2003-05-28 | Boehringer Ingelheim Pharma | Verfahren zur Reduktion des Liganden-leakage von Affinitätschromatographie-Matrices |
EP2048154B2 (en) * | 2002-02-05 | 2015-06-03 | Genentech, Inc. | Protein purification |
DK1601697T3 (da) * | 2003-02-28 | 2007-10-01 | Lonza Biologics Plc | Oprensning af antistof ved protein A- og ionbytningskromatografi |
DK3095793T3 (da) | 2003-07-28 | 2020-05-25 | Genentech Inc | Reducering af udvaskning af protein A under en protein A-affinitetskromatografi |
US9813410B2 (en) | 2014-06-26 | 2017-11-07 | Rakuten, Inc. | Information processing apparatus, information processing method, and information processing program |
-
2004
- 2004-06-24 DK DK16164203.8T patent/DK3095793T3/da active
- 2004-06-24 ES ES16164203T patent/ES2786568T3/es not_active Expired - Lifetime
- 2004-06-24 PT PT161642038T patent/PT3095793T/pt unknown
- 2004-06-24 EP EP20158848.0A patent/EP3722309A1/en not_active Withdrawn
- 2004-06-24 PL PL04777121.7T patent/PL1648940T3/pl unknown
- 2004-06-24 SI SI200432332A patent/SI1648940T1/sl unknown
- 2004-06-24 EP EP04777121.7A patent/EP1648940B1/en not_active Revoked
- 2004-06-24 LT LTEP16164203.8T patent/LT3095793T/lt unknown
- 2004-06-24 AU AU2004265253A patent/AU2004265253B2/en not_active Expired
- 2004-06-24 US US10/877,532 patent/US7485704B2/en active Active
- 2004-06-24 HU HUE16164203A patent/HUE050171T2/hu unknown
- 2004-06-24 PL PL16164203T patent/PL3095793T3/pl unknown
- 2004-06-24 HU HUE04777121A patent/HUE029951T2/en unknown
- 2004-06-24 CA CA2531595A patent/CA2531595C/en not_active Expired - Lifetime
- 2004-06-24 EP EP16164203.8A patent/EP3095793B1/en not_active Expired - Lifetime
- 2004-06-24 WO PCT/US2004/020480 patent/WO2005016968A2/en active Application Filing
- 2004-06-24 SI SI200432496T patent/SI3095793T1/sl unknown
- 2004-06-24 JP JP2006521841A patent/JP4599355B2/ja not_active Expired - Lifetime
- 2004-06-24 DK DK04777121.7T patent/DK1648940T3/da active
-
2008
- 2008-11-12 US US12/269,752 patent/US7807799B2/en not_active Expired - Lifetime
-
2020
- 2020-04-14 HR HRP20200589TT patent/HRP20200589T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
EP1648940B1 (en) | 2016-04-27 |
EP3722309A1 (en) | 2020-10-14 |
HUE029951T2 (en) | 2017-04-28 |
US7485704B2 (en) | 2009-02-03 |
DK3095793T3 (da) | 2020-05-25 |
WO2005016968A3 (en) | 2005-04-21 |
EP3095793A1 (en) | 2016-11-23 |
PL1648940T3 (pl) | 2016-12-30 |
SI3095793T1 (sl) | 2020-07-31 |
SI1648940T1 (sl) | 2016-08-31 |
CA2531595C (en) | 2015-12-08 |
JP2007526897A (ja) | 2007-09-20 |
US7807799B2 (en) | 2010-10-05 |
US20090099344A1 (en) | 2009-04-16 |
AU2004265253B2 (en) | 2011-09-01 |
WO2005016968A2 (en) | 2005-02-24 |
ES2786568T3 (es) | 2020-10-13 |
CA2531595A1 (en) | 2005-02-24 |
HRP20200589T1 (hr) | 2020-07-10 |
PT3095793T (pt) | 2020-05-04 |
HUE050171T2 (hu) | 2020-11-30 |
AU2004265253A1 (en) | 2005-02-24 |
US20050038231A1 (en) | 2005-02-17 |
JP4599355B2 (ja) | 2010-12-15 |
EP3095793B1 (en) | 2020-03-25 |
EP1648940A2 (en) | 2006-04-26 |
PL3095793T3 (pl) | 2020-09-07 |
LT3095793T (lt) | 2020-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1648940T3 (da) | Reduktion af udvaskning af protein A under protein A-affinitetskromatografi | |
US20220324905A1 (en) | Enhanced protein purification through a modified protein a elution | |
JP4460302B2 (ja) | タンパク質精製法 | |
EP0950067B1 (en) | Affinity purification of polypeptide on protein a matrix | |
JP2005526030A5 (da) | ||
AU2011253773A1 (en) | Reducing protein a leaching during protein a affinity chromatography | |
ES2578933T3 (es) | Reducción de la lixiviación de la proteína A durante la cromatografía de afinidad con proteína A |